COST EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS TREATMENT FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER AFTER FAILURE OF DOCETAXEL USING DATA FROM REAL LIFE TREATMENT PRAXIS IN SWEDEN

被引：1
|
作者：
Persson, U. [1 ]
Nilsson, S. [2 ]
Prutz, C. [3 ]
Hjortsberg, C. [3 ]
机构：
[1] Swedish Inst Hlth Econ, Lund, Sweden
[2] Dept Oncol Pathol, Stockholm, Sweden
[3] Janssen Cilag AB, Sollentuna, Sweden
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.655
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [31] Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective "Real Life" analysis of activity and safety
    Fabbri, M. A.
    Cortesi, E.
    Marchetti, P.
    Santini, D.
    Gamucci, T.
    Angelini, F.
    Longo, F.
    Milano, A.
    Mancini, M. L.
    Giuli, A.
    Quadrini, S.
    Sperduti, I.
    Pellegrino, A.
    Ratta, R.
    Primi, F.
    Chilelli, M. G.
    Ruggeri, E. M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S490 - S490
  • [32] COST-EFFECTIVENESS OF NIRAPARIB PLUS ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Duru, E.
    Mattingly, T. J.
    Malone, D. C.
    VALUE IN HEALTH, 2024, 27 (06) : S62 - S62
  • [33] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [34] COST-EFFECTIVENESS EVALUATION OF ENZALUTAMIDE AND ABIRATERONE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
    Gay, J. G.
    Schultz, N. M.
    Braun, S.
    VALUE IN HEALTH, 2018, 21 : S29 - S30
  • [35] An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy.
    Li, Tracy
    Thompson, Melissa
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian San
    He, Jianming
    Saadi, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [36] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [37] Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer
    Ramamurthy, Chethan
    Handorf, Elizabeth A.
    Correa, Andres F.
    Beck, J. Robert
    Geynisman, Daniel M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (10) : 688 - 695
  • [38] COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY
    Silva Miguel, L.
    Paquete, A. T.
    Borges, M.
    VALUE IN HEALTH, 2019, 22 : S611 - S612
  • [39] Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
    Rudakova, A. V.
    Meshkov, D. O.
    Mishugin, S. V.
    ONKOUROLOGIYA, 2014, 10 (03): : 73 - 77
  • [40] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345